MyFinsight
Home
Blog
About
Proceeds from june 2026
pipe-June Two Thousand And...
$4,000K
Net cash provided by
financing activities
$3,543K
(70760.00%↑ Y/Y)
Canceled cashflow
$457K
Net increase
(decrease) in cash and cash...
$3,224K
(212.49%↑ Y/Y)
Canceled cashflow
$319K
Payments of offering
costs-June Two Thousand And...
$395K
Payments of offering
costs-January Two Thousand...
$62K
Loss on january 2026
inducement offer
$5,754K
Valuation loss on june 2026
pipe
$5,423K
Unrealized loss subsequent
to receipt of above...
-$2,766K
Issuance and offering
costs
$651K
Accounts payable and
accrued expenses
$288K
(145.71%↑ Y/Y)
Prepaid expenses and
other current assets
-$112K
(79.41%↑ Y/Y)
Stock-based compensation
$14K
(-91.46%↓ Y/Y)
Net cash used in
operating activities
-$319K
(91.19%↑ Y/Y)
Canceled cashflow
$15,008K
Net loss
-$6,266K
(-237.06%↓ Y/Y)
something is missing
-$5,754K
Change in fair value of
common stock warrant...
$3,083K
(134.63%↑ Y/Y)
Accounts receivable and
other receivables
$134K
(-67.87%↓ Y/Y)
Inventories
$90K
(-84.62%↓ Y/Y)
Back
Back
Cash Flow
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)
source: myfinsight.com